Concurrent PET D2/D3 Receptor Imaging and fMRI Smoking Cue Reactivity in Smokers
| Status: | Completed |
|---|---|
| Conditions: | Smoking Cessation, Tobacco Consumers |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 50 |
| Updated: | 5/5/2014 |
| Start Date: | January 2014 |
| End Date: | March 2014 |
| Contact: | Marc J Kaufman, Ph.D. |
| Email: | kaufman@mclean.harvard.edu |
| Phone: | 617-855-3469 |
This trial aims to determine whether dopamine D3 receptors are elevated in smokers versus
nonsmokers and whether correlations exist between D3 receptor binding potential (BP) and
functional MRI (fMRI) reactivity to smoking cues, which has been associated with smoking
relapse vulnerability.
Neuroimaging measures of D3 BP and smoking cue fMRI reactivity will be collected
concurrently in otherwise healthy nicotine-dependent smokers and age-matched nonsmokers
using a 3 Tesla MRI scanner configured to conduct fMRI and Positron Emission Tomography
(PET).
We will measure D3 receptor BP using radiolabeled [11C]-(+)-PHNO, which has a relatively
higher affinity for D3 versus D2 receptors.
We hypothesize that D3 BP will be elevated in smokers versus nonsmokers and that in smokers,
there will be a positive correlation between smoking cue fMRI reactivity and D3 BP.
nonsmokers and whether correlations exist between D3 receptor binding potential (BP) and
functional MRI (fMRI) reactivity to smoking cues, which has been associated with smoking
relapse vulnerability.
Neuroimaging measures of D3 BP and smoking cue fMRI reactivity will be collected
concurrently in otherwise healthy nicotine-dependent smokers and age-matched nonsmokers
using a 3 Tesla MRI scanner configured to conduct fMRI and Positron Emission Tomography
(PET).
We will measure D3 receptor BP using radiolabeled [11C]-(+)-PHNO, which has a relatively
higher affinity for D3 versus D2 receptors.
We hypothesize that D3 BP will be elevated in smokers versus nonsmokers and that in smokers,
there will be a positive correlation between smoking cue fMRI reactivity and D3 BP.
Inclusion Criteria:
- competent to provide written informed consent
- Smokers: self-report of smoking 15 or more cigarettes/day for the past year,
self-report of smoking first cigarette of the day within 30 minutes of awakening,
meets DSM-IV criteria for Nicotine Dependence, provides expired breath carbon
monoxide reading of > 10 ppm at enrollment
- Nonsmokers: self-report of consuming <100 cigarettes in their lifetime, none in the
last 6 months, provides expired breath carbon monoxide reading of < 9 ppm at
enrollment
- Women of childbearing potential: negative STAT serum beta-human chorionic
gonadotrophin pregnancy test before scanning
Exclusion Criteria:
- pregnant or able to become pregnant and not willing to undergo blood pregnancy test
- unstable medical illness with likely hospitalization for treatment within 6 months
- life-threatening arrhythmia, cerebro-vascular or cardiovascular event within 6 months
of enrollment; liver function tests elevated over 2.5x normal; CNS tumor or seizure
disorder
- users of other tobacco- or nicotine-containing products (gum, patches, e-cigarettes)
- lifetime history of DSM-IV bulimia, organic mental disorder, brain injury or
psychotic disorder
- 6 month history of non-nicotine substance use disorder or major depression
- history of multiple adverse drug reactions
- current use of excluded concomitant medications (smoking cessation medications)
- known history of allergic reaction to the PET ligand [11C]-PHNO, its components, or
any medication
We found this trial at
3
sites
McLean Hospital McLean Hospital is a comprehensive psychiatric hospital committed to providing easy access to...
Click here to add this to my saved trials
Click here to add this to my saved trials
Charlestown, Massachusetts 02129
Click here to add this to my saved trials